There were 17 ( 5 % ) major cardiac adverse events in the bioresorbable scaffold group compared with five ( 3 % ) events in the metallic stent group , with the most common adverse events being myocardial infarction ( 15 cases [ 4 % ] vs two cases [ 1 % ] , respectively ) and clinically indicated target-lesion revascularisation ( four cases [ 1 % ] vs three cases [ 2 % ] , respectively ) .